1. Adenovirus-mediated interleukin 21 gene transfer enhances antitumor immunity and reduces tumorigenicity of Hepa1–6 in mice
   Jiyu Ju et al, 2016, Oncology Letters CrossRef
2. Profiles of serum soluble programmed death‐1 and programmed death‐ligand 1 levels in chronic hepatitis B virus‐infected patients with different disease phases and after anti‐viral treatment
   Juan Xia et al, 2020, Alimentary Pharmacology & Therapeutics CrossRef
3. The association between interleukin‐21 (rs2055979G/T) gene polymorphism and the risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus
   Noha M. Bakr et al, 2019, Journal of Cellular Biochemistry CrossRef
4. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
   Mengke Niu et al, 2022, Frontiers in Immunology CrossRef
5. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
   Muhammad Khan et al, 2020, Frontiers in Immunology CrossRef
6. Biological effects of IL-21 on immune cells and its potential for cancer treatment
   Meichen Ma et al, 2024, International Immunopharmacology CrossRef
7. Association between interleukin‐21 gene polymorphisms (rs12508721) and HBV‐related hepatocellular carcinoma
   Q. X. Zhang et al, 2016, International Journal of Immunogenetics CrossRef
8. Advances in engineering local drug delivery systems for cancer immunotherapy
   Peter Abdou et al, 2020, WIREs Nanomedicine and Nanobiotechnology CrossRef
9. An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
   Hongchuan Liu et al, 2021, International Immunopharmacology CrossRef
10. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
    Yiting Geng et al, 2015, International Journal of Clinical Oncology CrossRef
11. The Soluble Form of the EIAV Receptor Encoded by an Alternative Splicing Variant Inhibits EIAV Infection of Target Cells
    Yue-Zhi Lin et al, 2013, PLoS ONE CrossRef
12. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
    Katherine E. Lewis et al, 2018, OncoImmunology CrossRef
13. Cytokines in Cancer Immunotherapy
    Raki Sudan, 2020, Systems and Synthetic Immunology CrossRef
14. Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer
    Lisa A. Santry et al, 2024, Frontiers in Microbiology CrossRef
15. GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells
    Choong-Hyun Koh et al, 2020, Cancer Immunology Research CrossRef
16. The PD-1/PD-Ls pathway and autoimmune diseases
    Suya Dai et al, 2014, Cellular Immunology CrossRef
17. IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
    Michela Croce et al, 2015, Journal of Immunology Research CrossRef
18. Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma
    Fuyou Zhao et al, 2016, Oncology Letters CrossRef
19. Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma
    Kai Hou et al, 2024, BioFactors CrossRef
20. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
    Xinxin Zhu et al, 2017, Oncotarget CrossRef
21. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
    Muhammad Khan et al, 2021, Frontiers in Immunology CrossRef